Market capitalization | $530.29m |
Enterprise Value | $248.66m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.65 |
Dividend yield | 0.00% |
Last dividend (FY23) | $15.12 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-78.82m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Talaris Therapeutics Inc forecast:
8 Analysts have issued a Talaris Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -80 -80 |
40%
40%
|
EBIT (Operating Income) EBIT | -79 -79 |
34%
34%
|
Net Profit | -64 -64 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad in 2002 and is headquartered in Louisville, KY.
Head office | United States |
CEO | Sandeep Kulkarni |
Employees | 52 |
Founded | 2021 |
Website | www.tourmalinebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.